Related Experiment Videos
Markers for hepatocellular carcinoma
Insights
Alpha fetoprotein (AFP) is a key marker for hepatocellular cancer (HCC) detection and monitoring. Early screening in high-risk populations significantly improves survival rates for HCC patients.
Area of Science:
- Hepatology
- Oncology
- Biomarker Discovery
Background:
- Hepatocellular cancer (HCC) is a prevalent global cancer, particularly in Asia and Africa.
- Key risk factors include hepatitis B, alcohol consumption, cirrhosis, and aflatoxin exposure.
- Early detection of HCC remains a challenge, impacting treatment outcomes.
Purpose of the Study:
- To evaluate the utility of Alpha fetoprotein (AFP) as a biomarker for hepatocellular cancer (HCC).
- To assess the effectiveness of screening high-risk populations for early HCC detection.
- To explore novel diagnostic and therapeutic strategies for HCC.
Main Methods:
- Analysis of AFP levels in serum for HCC diagnosis and monitoring.
- Comparison of AFP with other potential serum and tissue markers.
- Evaluation of screening programs in high-risk populations.
- Investigating immunodetection and immunotherapy approaches for HCC.
Main Results:
- AFP is a significant marker, but often elevated late in HCC progression.
- Screening high-risk groups in China led to a dramatic increase in survival rates post-resection.
- Ultrasonography shows higher sensitivity than immunodetection for HCC.
- AFP levels effectively monitor treatment response and indicate recurrence.
Conclusions:
- AFP is a valuable tool for HCC monitoring, especially for AFP-producing tumors.
- Early detection through screening significantly improves HCC patient survival.
- Further research into AFP-conjugated therapies shows promise for HCC treatment.
Abstract:
Markers for hepatocellular cancer include the best and worst of cancer detection. Although hepatocellular cancer is relatively infrequent compared to other cancers in the western world, HCC has a very high incidence in parts of Asia and Africa. It is estimated to be one of the most common cancer worldwide. High risk factors for HCC include previous hepatitis B infection, heavy alcohol consumption, cirrhosis, and aflatoxin exposure. Alpha fetoprotein may be the best human cancer marker that appears in the serum, but levels of this marker are often not elevated until the tumor is beyond surgical treatment. No other serum or tissue marker is particularly useful. Screening of high-risk populations in China has detected previously undiagnosed HCC in 1,000 of 5 million individuals tested and has led to an increase in survival from 5.5 to 61.6% with surgical resection over those who are later diagnosed with HCC without screening. Elevations of AFP due to yolk sac tumors may be differentiated from those due to HCC on the basis of Concanavalin A reactivity. Immunodetection using radiolabeled anti-AFP and immunoscintigraphy have given inconsistent results that are not as sensitive as ultrasonography in detecting HCC in the liver. Various enzymes, isoenzymes, and other markers may be useful as adjuncts to diagnosis in selected cases, but are not generally as good as AFP alone. If a patient has an AFP-producing tumor, the serum levels of AFP provide an excellent means of monitoring its progression. If the serum AFP levels drop to normal and stay there, cure is almost certain. If, however, the serum AFP level does not fall at the normal catabolic rate after therapy, or subsequently rises, regrowth of metastases are indicated. Immunotherapy using anti-AFP has not been shown to induce remission, but experimental studies indicate that drug-conjugated anti-AFP is effective in inhibiting growth of AFP-producing tumors. Clinical trials using drug-conjugated anti-AFP are now underway. Monoclonal antibodies have not yet identified the "antigens" useful for the diagnosis or treatment of HCC, but epitopes identified by monoclonal antibodies have been studied experimentally in rats which indicate multiple cellular lineages to HCC in cases of experimental chemically induced hepatocarcinoma.